Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa

Journal of the College of Physicians and Surgeons Pakistan

Volumn 21, Issue 9, 2011, Pages 531-534

  Gill, Maria Mushtaq ^a   Usman, Javaid ^a   Kaleem, Fatima ^a   Hassan, Afreenish ^a   Khalid, Ali ^a   Anjum, Rabia ^a   Fahim, Qanita ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Antibiogram; Colistin; Multi Drug resistant Pseudomonas aeruginosa; Piperacillin Tazobactam

Indexed keywords

AMIKACIN; AZTREONAM; CEFOPERAZONE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CROSS-SECTIONAL STUDY; DISK DIFFUSION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; PUS; SECRETION; SPUTUM; TRACHEOBRONCHIAL TOILET; URINE;

ANTI-BACTERIAL AGENTS; CEFOPERAZONE; COLISTIN; CROSS-SECTIONAL STUDIES; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; HUMANS; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SULBACTAM;

EID: 80052712425     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Lister PD, Wolter DJ, Hanson ND. Antibacterial resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22:582-680.
2. Tam VH, Chang KT, Abdelraouf K, Brioso CG, Ameka M, McCaskey LA, et al. Prevalence, mechanism and susceptibility of multidrug resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010; 54:1160-4. Epub 2010 Jan 19.
3. Nadeem SG, Qasmi SA, Afaque F, Saleem M, Hakim ST. Comparison of the in vitro susceptibility of Clinical isolates of Pseudomonas aeruginosa in a local hospital setting in Karachi, Pakistan. Br J Med Practitioners 2009; 2:35-9.
4. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11:17-32.
5. Nwankwo EOK, Shuaibu SA. Antibiotic susceptibility pattern of clinical isolates of Pseudomonas aeruginosa in a tertiary health institution in Kano Nigeria. J Med Biomed Sci 2010; 17:37-40.
6. Aloush V, Navon-vanezia S, Siegman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-8.
7. Magiorakos AP. Multidrug-resistant (MDR), extensively drugresistant (XDR) and pandrug-1 resistant (PDR) bacteria in healthcare settings. Expert proposal for a standardized international terminology [Internet]. 2011. Available online at www.escmid.org/ESCD_ Definitions_ MDRXDRPDR _2010_pdf
8. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial disk diffusion susceptibility tests. Wayne (PA): CLSI; 2009.
9. ASM Submits Comments on "Multidrug-resistant (MDR), extensively drug-resistant (XDR) and pandrug-resistant (PDR) bacteria in healthcare settings [Internet]. [updated 2010 Aug 17]. Washington: American Society For Microbiology; 2010. Available from: http://www.microbemagazine.org/index.php/10-2010-publicaffairs-report/2942-asm-comments-on-ecdc-standardizedinternational-terminology-for-mdr-xdr-and-pdr-bacteria-in-healthcare-settings
10. Farida A, Mir A. Susceptibility pattern of Pseudomonas aeruginosa against various antibiotics. Afr J Microbiol Res 2010; 4:1005-12.
11. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25:1353- 64.
12. Falages ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoullou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC Infect Dis 2005; 5:24.
13. Hachem RY, Chemaley RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51:1905-11.
14. Farhatullah, Malik SA, Ahmed J. Antimicrobial susceptibility and ESBL prevalence in Pseudomonas aeruginosa isolated from burn patients in the North West of Pakistan. J Burns 2009; 25:1020-5. Epub 2009 June 6.
15. Amutha R, Padmakrishnan, Murugan T, Renugadevi MP. Studies on multidrug resistant Pseudomonas aeruginosa from pediatric population with special reference to extended spectrum beta lactamase. Indian J Sci Technol 2009; 2:11-3.
16. Kirikae T, Mizuguchi Y, Arakawa Y. Investigation of isolation rates of Pseudomonas aeruginosa with and without multidrug resistance in medical facilities and clinical laboratories in Japan. J Antimicrob Chemother 2008; 61:612-5. Epub 2008 Jan 31.
17. Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27:224-8. Epub 2006 Feb 7.